1 / 39

Can the Specialty Beast Be Tamed?

Can the Specialty Beast Be Tamed?. Steven B. Miller, MD Express Scripts. Specialty Growth Continues to Outpace Traditional Drug Market. 27%. 21%. Source: Express Scripts analysis of IMS data. 2. Specialty Growth Continues to Outpace Traditional Drug Market. 27%. 21%.

chelsi
Download Presentation

Can the Specialty Beast Be Tamed?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Can the Specialty Beast Be Tamed? Steven B. Miller, MD Express Scripts

  2. Specialty Growth Continues to Outpace Traditional Drug Market 27% 21% Source: Express Scripts analysis of IMS data. 2

  3. Specialty Growth Continues to Outpace Traditional Drug Market 27% 21% Source: Express Scripts analysis of IMS data. 3

  4. Specialty Growth Continues to Outpace Traditional Drug Market 27% 21% Source: Express Scripts analysis of IMS data. 4

  5. Agenda

  6. What Are Specialty Medications?

  7. Overall Specialty Trend: 14% PMPY 7

  8. “Specialty”: Now the #1 Therapy Class PMPY

  9. Utilization Drove Trend More Than Last Year PMPY 9

  10. Key Specialty Therapy Classes2006:2007 + 18% + 16% + 20% PMPY - 10% + 6% + 17% + 1% 10 PMPY

  11. Key Specialty Therapy Classes2006:2007 + 18% + 16% + 20% PMPY - 10% + 6% + 17% + 1% 11 PMPY

  12. Expanded and Earlier Use Inflammatory Conditions 12

  13. Expanded and Earlier Use Inflammatory Conditions 13

  14. Price Drove Trend Multiple Sclerosis 14

  15. Price Drove Trend Multiple Sclerosis 15

  16. Price Drove Trend Multiple Sclerosis 16

  17. Price, Place and Product Cancer 17

  18. Price, Place and Product Cancer 18

  19. Price, Place and Product Cancer 19

  20. Safety Changed the Landscape Blood Cell Deficiency 20

  21. Safety Changed the Landscape Blood Cell Deficiency 21

  22. Prevalence and Price Overwhelmed Mix Growth Hormone 22

  23. Prevalence and Price Overwhelmed Mix Growth Hormone 23

  24. Growth Hormone Use Is Rapidly Moving Into Older Patients Users above age 20

  25. Medical Shifted to Pharmacy Anticoagulants 25

  26. Medical Shifted to Pharmacy Anticoagulants 26

  27. Where are the Patients Going? Hepatitis C 27

  28. Where are the Patients Going? Hepatitis C 28

  29. Hepatitis C Prevention Is WorkingUS has 3.2 Million Chronically Infected and 10,000 Annual Deaths http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdf accessed March 24, 2008

  30. Hepatitis C Prevention Is WorkingUS has 3.2 Million Chronically Infected and 10,000 Annual Deaths http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdf accessed March 24, 2008

  31. Specialty Growth Continues to Outpace Traditional Drug Market 27% 21% Source: Express Scripts analysis of IMS data. 31

  32. Follow-on Biologic Savings Opportunity ESI studied four classes of specialty drugs

  33. Follow-on Biologic Savings Opportunity ESI studied four classes of specialty drugs

  34. In the first ten years: $71 Billion Savings Inflation and prevalence drive trend in this model $ Billions

  35. Every Study Says “Billions”

  36. Key Issues

  37. 2007 Was An Active Legislative Year for Follow-On Biologics High-level excerpts of selected issues; not a complete description of legislative proposals.

  38. 2008 Biogenerics Legislation

  39. Conclusions

More Related